Literature DB >> 14508218

Fecal calprotectin levels in healthy children studied with an improved assay.

Ulrika Lorentzon Fagerberg1, Lars Lööf, Rumjana Djilali Merzoug, Lars-Olof Hansson, Yigael Finkel.   

Abstract

BACKGROUND: Calprotectin is a protein abundant in neutrophils. Fecal calprotectin can be used as a marker of gastrointestinal inflammation, and an improved assay has recently been developed. The aim of this study was to establish reference values for fecal calprotectin in healthy children aged between 4 and 17 years.
METHODS: Fecal samples were obtained from 117 healthy children classified into four age groups: 4 to 6 years, 7 to 10 years, 11 to 14 years, and 15 to 17 years. A health questionnaire was used to ensure that these children fulfilled the inclusion criterion and did not have intercurrent disease, nasal or menstrual bleeding, or nonsteroidal anti-inflammatory drug medication before the sampling period. Calprotectin was analyzed using a quantitative enzyme-linked immunosorbent assay (Calprest, Eurospital SpA, Trieste, Italy). Children with fecal calprotectin values >50 microg/g were asked to deliver an additional sample.
RESULTS: The overall median fecal calprotectin concentration was 13.6 microg/g (95% confidence interval, 9.9-19.5 microg/g) in the 117 children. In the different age groups, 4 to 6 years, 7 to 10 years, 11 to 14 years, and 15 to 17 years, the median calprotectin concentrations were 28.2, 13.5, 9.9, and 14.6 microg/g, respectively. Of these children, 104 (89%) had a concentration <50 microg/g. The remaining 13 children with a calprotectin concentration >50 microg/g delivered one additional fecal sample. All showed a lower concentration in the second sample except for one teenager who later proved to have proctitis.
CONCLUSIONS: The suggested cutoff level for adults (<50 microg/g) can be used for children aged from 4 to 17 years regardless of sex. A fecal calprotectin concentration >50 microg/g warrants follow-up.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508218     DOI: 10.1097/00005176-200310000-00013

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  39 in total

1.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

2.  Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population.

Authors:  Oriano Radillo; Lorella Pascolo; Stefano Martelossi; Sara Dal Bo; Alessandro Ventura
Journal:  J Clin Lab Anal       Date:  2016-02-15       Impact factor: 2.352

3.  Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?

Authors:  Chee Y Ooi; Tamara Pang; Steven T Leach; Tamarah Katz; Andrew S Day; Adam Jaffe
Journal:  Dig Dis Sci       Date:  2015-08-14       Impact factor: 3.199

4.  Fecal biomarkers for the diagnosis and management of inflammatory bowel disease.

Authors:  Gert Van Assche
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-06

Review 5.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

Review 6.  Calprotectin levels in necrotizing enterocolitis: a systematic review of the literature.

Authors:  Vasilios Pergialiotis; Panagiotis Konstantopoulos; Nikoleta Karampetsou; Diamanto Koutaki; Eleana Gkioka; Despina N Perrea; Nikolaos Papantoniou
Journal:  Inflamm Res       Date:  2016-06-21       Impact factor: 4.575

7.  Fecal calprotectin level in healthy children aged less than 4 years in South Korea.

Authors:  Joo Young Song; Yoo Mi Lee; You Jin Choi; Su Jin Jeong
Journal:  J Clin Lab Anal       Date:  2017-01-16       Impact factor: 2.352

8.  The Use of Fecal Calprotectin Levels in the Fontan population.

Authors:  Carlos Miranda; Anas Taqatqa; Adrian Chapa-Rodriguez; Jacob P Holton; Sawsan M Awad
Journal:  Pediatr Cardiol       Date:  2017-12-28       Impact factor: 1.655

Review 9.  Probiotic supplementation in children with cystic fibrosis-a systematic review.

Authors:  Anitha Ananthan; Haribalakrishna Balasubramanian; Shripada Rao; Sanjay Patole
Journal:  Eur J Pediatr       Date:  2016-08-30       Impact factor: 3.183

10.  Description of Dientamoeba fragilis cyst and precystic forms from human samples.

Authors:  D Stark; L S Garcia; J L N Barratt; O Phillips; T Roberts; D Marriott; J Harkness; J T Ellis
Journal:  J Clin Microbiol       Date:  2014-05-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.